BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tu G, Fu T, Yang F, Yang J, Zhang Z, Yao X, Xue W, Zhu F. Understanding the Polypharmacological Profiles of Triple Reuptake Inhibitors by Molecular Simulation. ACS Chem Neurosci 2021;12:2013-26. [PMID: 33977725 DOI: 10.1021/acschemneuro.1c00127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Phusi N, Hashimoto Y, Otsubo N, Imai K, Thongdee P, Sukchit D, Kamsri P, Punkvang A, Suttisintong K, Pungpo P, Kurita N. Structure-based drug design of novel M. tuberculosis InhA inhibitors based on fragment molecular orbital calculations. Comput Biol Med 2023;152:106434. [PMID: 36543008 DOI: 10.1016/j.compbiomed.2022.106434] [Reference Citation Analysis]
2 Sousa GHM, Gomes RA, de Oliveira EO, Trossini GHG. Machine learning methods applied for the prediction of biological activities of triple reuptake inhibitors. Journal of Biomolecular Structure and Dynamics 2022. [DOI: 10.1080/07391102.2022.2154269] [Reference Citation Analysis]
3 Ko M, Kim Y, Kim HH, Jeong S, Ahn D, Chung SJ, Kim H. Network pharmacology and molecular docking approaches to elucidate the potential compounds and targets of Saeng-Ji-Hwang-Ko for treatment of type 2 diabetes mellitus. Computers in Biology and Medicine 2022;149:106041. [DOI: 10.1016/j.compbiomed.2022.106041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jia L, Wang L, Jiang Y, Xu L, Cai Y, Chen Y, Jin J, Sun H, Zhu J. Exploring PI3Kγ binding preference with Eganelisib, Duvelisib, and Idelalisib via energetic, pharmacophore and dissociation pathway analyses. Computers in Biology and Medicine 2022;147:105642. [DOI: 10.1016/j.compbiomed.2022.105642] [Reference Citation Analysis]
5 Gervasoni S, Malloci G, Bosin A, Vargiu AV, Zgurskaya HI, Ruggerone P. Recognition of quinolone antibiotics by the multidrug efflux transporter MexB of Pseudomonas aeruginosa. Phys Chem Chem Phys 2022;24:16566-75. [PMID: 35766032 DOI: 10.1039/d2cp00951j] [Reference Citation Analysis]
6 Tan S, Zhang Q, Wang J, Gao P, Xie G, Liu H, Yao X. Molecular Modeling Study on the Interaction Mechanism between the LRRK2 G2019S Mutant and Type I Inhibitors by Integrating Molecular Dynamics Simulation, Binding Free Energy Calculations, and Pharmacophore Modeling. ACS Chem Neurosci 2022;13:599-612. [PMID: 35188741 DOI: 10.1021/acschemneuro.1c00726] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Xue W, Fu T, Deng S, Yang F, Yang J, Zhu F. Molecular Mechanism for the Allosteric Inhibition of the Human Serotonin Transporter by Antidepressant Escitalopram. ACS Chem Neurosci 2022;13:340-51. [PMID: 35041375 DOI: 10.1021/acschemneuro.1c00694] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 33.0] [Reference Citation Analysis]
8 Lodhi R, Prakash M, Samanta S. Diastereoselective desymmetrization reactions of prochiral para-quinamines with cyclopropenes generated in situ: access to fused hydroindol-5-one scaffolds. Org Biomol Chem 2021;19:7129-33. [PMID: 34369544 DOI: 10.1039/d1ob01322j] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]